Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

CF-Emerging therapies: Modulation inflammation.

M Fayon1,

  • 1C.R.C.M. pédiatrique & Centre de Recherche (CEDRE), CHU de Bordeaux-Université Victor Segalen Bordeaux 2, Laboratoire de Physiologie Cellulaire Respiratoire, Place Amélie Raba Léon, 33076 Bordeaux Cedex, France. michael.fayon@chu-bordeaux.fr

Paediatric Respiratory Reviews
|June 27, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Natural history].

Revue des maladies respiratoires·2024
Same author

[Allergic Broncho-Pulmonary Aspergillosis (ABPA) in cystic fibrosis: Mechanisms, diagnosis and therapeutic options].

Revue des maladies respiratoires·2021
Same author

Population pharmacokinetics of ceftazidime in critically ill children: impact of cystic fibrosis.

The Journal of antimicrobial chemotherapy·2020
Same author

Variability of ciprofloxacin pharmacokinetics in children: impact on dose range in sickle cell patients.

The Journal of antimicrobial chemotherapy·2018
Same author

Remodelling and inflammation in preschoolers with severe recurrent wheeze and asthma outcome at school age.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2018
Same author

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie·2017
Same journal

Image-guided pediatric airway endoscopy: A review.

Paediatric respiratory reviews·2026
Same journal

Bronchoscopic and interventional management of tracheobronchomalacia in children with bronchopulmonary dysplasia: a review of evidence.

Paediatric respiratory reviews·2026
Same journal

Hand in glove: New imaging techniques and airway endoscopy.

Paediatric respiratory reviews·2026
Same journal

Bronchopulmonary dysplasia associated pulmonary hypertension: implications across the lifespan.

Paediatric respiratory reviews·2026
Same journal

How to monitor response to biologics in children with severe asthma.

Paediatric respiratory reviews·2026
Same journal

Moving the goalposts from symptom control to preventing airway remodeling in preschool asthma.

Paediatric respiratory reviews·2026
See all related articles

Persistent inflammation drives cystic fibrosis (CF) lung disease. Early intervention with agents like macrolides may offer benefits, but further research is needed for other treatments.

Area of Science:

  • Pulmonology
  • Immunology
  • Pharmacology

Background:

  • Persistent and dysregulated inflammation is a key factor in cystic fibrosis (CF) lung disease progression.
  • Neutrophil accumulation in airways is a hallmark of advancing CF lung disease.

Purpose of the Study:

  • To review current understanding of CF airway inflammation.
  • To evaluate potential therapeutic agents for modulating inflammation in CF.

Main Methods:

  • Literature review of inflammatory processes in CF.
  • Analysis of existing and potential therapeutic strategies for CF lung disease.

Main Results:

  • Macrolides show promise as anti-inflammatory agents with a good safety profile for long-term use in CF.

Related Experiment Videos

  • Steroids are generally not recommended for CF, except in specific circumstances.
  • Leukotriene modifiers, N-acetylcysteine, anti-elastase, and anti-cytokines require further investigation.

    • Conclusions:

    • Early treatment of CF lung disease, before significant lung damage occurs, is crucial.
    • Targeting airway inflammation is a critical therapeutic goal in CF management.